Cited by 270Acute Lymphoblastic Leukemia researchGlobal Cancer Incidence and ScreeningLymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.

Racial and ethnic differences in survival of children with acute lymphoblastic leukemia

Open access

Abstract

Black children with acute lymphoblastic leukemia (ALL) have poor outcomes, but limited information is available for children from other racial and ethnic backgrounds, such as Hispanic and Asian. We undertook a retrospective cohort study of children with ALL treated on Children's Cancer Group therapeutic protocols to determine outcomes by racial and ethnic backgrounds of patients treated with contemporary risk-based therapy. In total, 8447 children (white, n = 6703; Hispanic, n = 1071; black, n = 506; and Asian, n = 167) with newly diagnosed ALL between 1983 and 1995 were observed for a median of 6.5 years. Analysis of disease outcome was measured as overall survival (OS) and event-free survival (EFS) and was adjusted for known predictors of outcome including clinical features, disease biology, socioeconomic status, and treatment era (1983-1989 vs 1989-1995). There was a statistically significant difference in survival by ethnicity (P < .001). Five-year EFS rates were: Asian, 75.1% ± 3.5%; white, 72.8% ± 0.6%; Hispanic, 65.9% ± 1.5%; and black, 61.5% ± 2.2%. Multivariate analysis revealed that when compared with white children, black and Hispanic children had worse outcomes and Asian children had better outcomes after adjusting for known risk factors. The poorer outcomes among black children were most apparent among patients with standard-risk features (relative risk [RR], 2.0; 95% confidence interval [CI], 1.6-2.5), whereas poorer outcomes in Hispanic children (RR, 1.4; 95% CI, 1.2-1.6) were most evident among patients with high-risk features. Asian children had better outcomes than all racial and ethnic groups among high-risk patients, particularly in the recent era (5-year EFS, 90.9% ± 6.1%). Racial and ethnic differences in OS and EFS persist among children with ALL who receive contemporary risk-based therapy. Future studies should focus on reasons—perhaps compliance or pharmacogenetics—for those differences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-02-0395

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 8

  1. Reaman, 1984, Racial variation in the frequency of immunological subtypes of childhood acute lymphoblastic leukemia., Prog Cancer Res Ther., 27, 163
  2. Sather, 1984, Differences in the presentation of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in black children and white children: a report from the Epidemiology Committee of the Children's Cancer Study Group., 179
  3. Falletta, 1984, Clinical and phenotypic features of childhood acute lymphocytic leukemia in whites, blacks, and Hispanics: a Pediatric Oncology Group study., Prog Cancer Res Ther., 27, 191
  4. Ries, 1999, SEER Cancer Statistics Review, 1973-1996.
  5. Hutchinson, 1996, Should therapy be intensified for patients with good risk ALL [abstract]?, Blood., 88, 668
  6. Lange, 1997, Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): a Children's Cancer Group study, CCG-1891 [abstract]., Blood., 90, 559
  7. Bostrom, 1998, Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL) [abstract]., Proc Am Soc Clin Oncol., 17, 527
  8. Kelsey, 1986, Methods in Observational Epidemiology: Retrospective Cohort Studies.

Cited by

Sorted by citations

Metadata

Authors
Bhatia, S., Sather, H. N., Heerema, N. A., Trigg, M. E., Gaynon, P. S., & Robison, L. L.
Affiliations
University of Southern California (US)
Corresponding author
Bhatia, Smita
Venue
Blood
Published
2002-09-15
Volume
100
Issue
6
Pages
1957-1964
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1995246501
Cited by
270
References
47
Citations by year
2026: 6 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 25 · 2019: 12 · 2018: 11 · 2017: 12 · 2016: 13 · 2015: 12 · 2014: 18 · 2013: 10 · 2012: 17
FWCI
8.68
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (U10CA013539, 5U10 CA 13539-2652)
Topics
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
acute lymphoblastic leukemia, racial disparities, ethnic differences, children, overall survival, event-free survival, Hispanic children, Black children, Asian children, socioeconomic status, pharmacogenetics, medication adherence
MeSH terms
Adolescent, Child, Child, Preschool, Chromosome Aberrations, Ethnicity, Female, Follow-Up Studies, Humans, Infant, Male, Prospective Studies, Retrospective Studies, Risk Factors, Social Class, Survival Analysis, Treatment Outcome, Disease-Free Survival, Racial Groups, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review